Heart Disease After Menopause: A Charleston Woman's Cardiometabolic Guide

Ashley Harwyn, PA-C  |  A4M Board Certified  |  SC PA License  |  July 7, 2026

Most women in midlife are watching for the wrong disease. We worry about breast cancer, and we should stay screened, but heart disease quietly kills far more women, and the risk climbs sharply after menopause. The hardest part is that the standard cholesterol panel your primary care doctor runs can look completely normal while your actual cardiovascular risk is rising. If you are a woman in Charleston in your forties or fifties who wants to know her real heart risk rather than the basic-panel version, this guide explains the numbers that matter, why menopause changes everything, and the specific workup we run at Solcara Health to see the whole picture.

Why heart disease is the number one killer of women after menopause

Cardiovascular disease is the leading cause of death for women in the United States and globally, and it accounts for roughly one in five deaths^[1]. That single fact surprises most women, and it should: fewer than half of women know that heart disease, not cancer, is their leading cause of death^[6].

The picture is getting more urgent, not less. In February 2026, the American Heart Association published a scientific statement projecting that nearly six in ten women in the United States will have some form of cardiovascular disease within the next twenty-five years, and that one in three women will die from it^[5]. More than sixty-two million American women are already living with some form of cardiovascular disease today^[5]. These are not distant statistics. They describe the women sitting in Lowcountry carpool lines and boardrooms right now.

What makes this especially relevant after menopause is timing. For much of a woman's life, estrogen provides a measure of cardiovascular protection, supporting healthy blood vessel function and a more favorable lipid profile. When estrogen declines through the menopause transition, that protection fades, and a woman's cardiovascular risk rises substantially^[2]. The years around menopause are precisely when the risk picture shifts, and precisely when most women are told their standard cholesterol panel looks fine. (If you are still in the earlier transition, our guide to perimenopause functional medicine in Mount Pleasant covers the hormonal side of this same window.)

How menopause rewrites your cardiovascular risk

The menopause transition is not just about hot flashes and sleep. It quietly changes the machinery that governs cardiovascular health, and understanding that change is the key to acting early.

Estrogen influences the cardiovascular system in several ways at once. It helps keep blood vessels flexible and responsive, supports the lining of the arteries, and nudges the lipid profile in a healthier direction. As estrogen falls during and after the menopause transition, these effects diminish, and the American Heart Association specifically identifies this loss of estrogen's vascular and lipid-modulating effects as a driver of rising cardiovascular risk in women^[2].

In practical terms, several things tend to shift together in the years around menopause. LDL and total cholesterol often rise. The pattern of cholesterol particles can shift toward smaller, denser, more atherogenic forms. Visceral fat, the metabolically active fat around the midsection, tends to increase, which worsens insulin sensitivity. Blood pressure frequently creeps up. None of these changes announces itself. A woman can feel essentially the same while her underlying cardiovascular risk profile is quietly reorganizing itself for the worse.

This is why the perimenopausal and postmenopausal years are the right moment to look closely, and why looking only at a standard cholesterol panel can be so misleading. The transition is when the risk changes, so the transition is when the measurement needs to get more precise.

The standard cholesterol panel: what it shows and what it misses

When your primary care doctor checks your cholesterol, you typically get a standard lipid panel: total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. This panel is useful, and it is better than nothing, but it was designed decades ago and it leaves out the measurements that modern cardiology increasingly considers the most predictive.

The core limitation is that LDL cholesterol measures the amount of cholesterol carried inside your LDL particles, not the number of particles. Two women can have identical LDL cholesterol numbers while one has far more actual particles depositing cholesterol into her artery walls. Cardiovascular risk tracks more closely with the number of atherogenic particles than with the cholesterol they carry, and this is exactly the information a standard panel does not give you.

The result is a panel that can read reassuringly normal while missing meaningful risk. For a woman navigating the cardiovascular shifts of menopause, that gap is not academic. It is the difference between acting on the real picture and being told everything is fine when it is not. The good news is that the measurements that close this gap are not exotic or experimental. They are available at standard labs. They are simply not part of the panel most doctors order by default.

ApoB: the biomarker your standard panel skips

If there is one number that deserves to be far better known among women, it is ApoB, or apolipoprotein B. ApoB is the structural protein that wraps around every atherogenic lipoprotein particle, including LDL and others. Because each of these particles carries exactly one ApoB molecule, measuring ApoB gives you a direct count of the total number of particles capable of depositing cholesterol into your artery walls.

That direct particle count is why ApoB has become so important. A 2019 analysis published in JAMA Cardiology, drawing on data from nearly four hundred thousand participants, found that ApoB was a stronger predictor of cardiovascular events than LDL cholesterol, particularly in people whose particle count and cholesterol level did not match^[3]. When those two measures disagree, and they often do in women with metabolic changes around menopause, the particle count carries the risk. A standard panel shows you the cholesterol. ApoB shows you the particles.

It is important to be clear about what ApoB is and is not. It is a biomarker, a measurement that sharpens the risk picture, not a diagnosis by itself. An ApoB result is interpreted in the context of your full health history, your other markers, and your individual situation, and what counts as an appropriate target is an individual clinical decision rather than a single universal cutoff. But as a window into cardiovascular risk that a standard panel simply does not open, it is hard to overstate its value.

Lp(a): the genetic risk most women never hear about

The second measurement almost no woman is told about is lipoprotein(a), written Lp(a) and spoken as "L-P-little-a." It is one of the most important inherited cardiovascular risk factors, and it is invisible to a standard panel.

Lp(a) is an LDL-like particle with an extra protein attached, and what makes it distinctive is that its level is largely genetic. Roughly eighty to ninety percent of your Lp(a) level is determined by inheritance, it is essentially set from childhood, and it does not respond meaningfully to the diet and exercise changes that improve most other lipid markers^[4]. Elevated Lp(a) is an independent, causal risk factor for cardiovascular disease, and on a per-particle basis it is considerably more atherogenic than ordinary LDL^[4]. It is thought to affect roughly one in five people, which means a substantial share of women carry an elevated level and have no idea.

Because it is genetic and stable, Lp(a) needs to be measured only once to know where you stand, and both the American College of Cardiology and the American Heart Association's 2026 guidance now recommend that adults measure Lp(a) at least once for cardiovascular risk assessment^[7]. Knowing you carry an elevated Lp(a) does not mean something is wrong with you today. It means you and your clinician can be more aggressive about every other modifiable risk factor, and it can explain a family history of early heart disease that never otherwise made sense. As with ApoB, Lp(a) is a biomarker that informs strategy, and what to do about a given level is an individual clinical decision.

Beyond lipids: the inflammatory and metabolic picture

Cardiovascular risk is not only about lipoproteins. It develops through several pathways at once, and a complete workup looks at the metabolic and inflammatory drivers alongside the particle count.

A few additional markers round out the picture. High-sensitivity C-reactive protein, or hs-CRP, is a marker of the low-grade inflammation that contributes to arterial damage. Fasting insulin and HbA1c reveal how well your metabolism is handling glucose, often flagging insulin resistance years before blood sugar rises into a diabetic range, which matters because the metabolic shifts of menopause frequently push insulin sensitivity in the wrong direction. Together, these markers connect the cardiovascular and metabolic stories that, in a woman's midlife, are really one story. The visceral fat that accumulates after menopause worsens insulin resistance, insulin resistance drives inflammation and unfavorable lipid changes, and the whole system moves together. Looking at lipids alone tells you part of the truth. Looking at the inflammatory and metabolic markers alongside them tells you considerably more.

The Women's Cardiometabolic Longevity Workup at Solcara

Peter Attia and the Medicine 3.0 approach he popularized argue that cardiovascular disease should be assessed and addressed decades before it becomes clinical, using the most predictive markers available rather than waiting for a standard panel to catch up. That framework is sound, and it is also written for a largely gender-neutral audience that, in practice, defaults to men. What has been missing is that same rigor translated specifically for women navigating the cardiovascular changes of menopause, with a local place to actually get it done. That translation is what we built.

The Women's Cardiometabolic Longevity Workup at Solcara is our name for a comprehensive panel that goes well beyond the standard lipid check. Where a conventional workup stops at total cholesterol, LDL, HDL, and triglycerides, our workup adds the measurements that actually reflect modern cardiovascular science: ApoB for direct particle count, Lp(a) for inherited risk, an advanced lipid particle assessment, hs-CRP for inflammation, and fasting insulin and HbA1c for the metabolic picture, all interpreted in the context of your hormonal transition rather than in isolation, alongside bioidentical hormone therapy when appropriate. We order these advanced labs directly. When the picture warrants deeper cardiovascular imaging, such as carotid intima-media thickness testing or a coronary calcium scan, we coordinate that through a longevity-aware cardiologist rather than performing it in-house, so you get the right test in the right setting.

The point of the workup is not to collect numbers. It is to give you and your clinician an accurate, actionable risk picture at the exact moment in life when the risk is changing, so that decisions about hormones, metabolism, and cardiovascular prevention can be made on real information.

How hormones, GLP-1 therapy, and cardiovascular care fit together

One of the most important things to understand in midlife is that hormone therapy, metabolic treatment, and cardiovascular prevention are not three separate appointments. They are one integrated decision, and the cardiometabolic workup is what ties them together.

Your hormonal status, your metabolic health, and your cardiovascular risk are deeply interconnected. The estrogen decline of menopause affects lipids and vascular function. Metabolic health, including insulin sensitivity and body composition, shapes both cardiovascular risk and how you feel day to day. Treatments that address one domain frequently influence the others, which is why the metabolic synergy of HRT and GLP-1 therapy matters so much in midlife. This is why we assess them together rather than in silos. A cardiometabolic workup that reveals rising particle count and worsening insulin sensitivity in a perimenopausal woman is not just a heart report. It is information that shapes the entire conversation about how to support her through the next several decades. Seeing the whole system at once is the entire point of a longevity-oriented practice, and it is what a fragmented, one-organ-at-a-time approach cannot offer.

When to escalate: imaging and the cardiology partnership

Advanced labs answer most of the questions for most women, but sometimes the picture calls for direct imaging of the arteries, and it is worth understanding where that fits.

Two tests come up most often. Carotid intima-media thickness testing, or CIMT, uses ultrasound to measure the thickness of the carotid artery wall as an early sign of atherosclerosis. A coronary artery calcium scan, or CAC, uses a low-dose CT to detect calcified plaque in the heart's own arteries. Both can add meaningful information when lab markers or personal and family history suggest a closer look is warranted. These are specialized imaging studies, and the right way to pursue them is through a longevity-aware cardiologist. At Solcara, we identify when this deeper look is appropriate and coordinate the referral, rather than performing the imaging ourselves, so that escalation happens in the proper clinical setting with the proper expertise.

How Solcara approaches cardiometabolic longevity in Charleston

For the women who come to us in Mount Pleasant and downtown Charleston, cardiometabolic care is not a bolt-on. It is woven into how we think about the whole person. A woman arriving for perimenopause support or hormone optimization is, in our model, also a candidate for a clear-eyed look at her cardiovascular and metabolic risk, because in midlife those questions are inseparable.

What that means in practice is a longer conversation than a fifteen-minute visit allows, a workup built for where she actually is in her hormonal life rather than a generic panel, and a plan that treats her cardiovascular future as a decades-long project rather than a single lab result, integrated into Solcara's longevity medicine program. Whether she is coming from the Old Village, Daniel Island, West Ashley, or downtown, the goal is the same: to give her the longevity-grade risk picture that the standard system, through no individual clinician's fault, is not set up to provide. Heart disease may be the number one killer of women after menopause, but the tools to see it coming are better than they have ever been, and using them well is exactly the kind of medicine we are here to practice.

Women's cardiometabolic health questions answered

The questions Charleston patients ask most often. Click any question to read Ashley's answer.

Your heart risk is knowable, and midlife is the time to know it

Heart disease is the leading cause of death for women, the risk rises after menopause, and the standard cholesterol panel most women rely on can miss it entirely. That combination is exactly why the years around menopause deserve a more precise look. The measurements that reveal the real picture, ApoB, Lp(a), advanced lipids, and the inflammatory and metabolic markers alongside them, are available now, and interpreted well, they turn a vague worry into an actionable plan.

You do not have to guess about your cardiovascular future, and you do not have to accept a basic-panel answer to a longevity-grade question. If you want to understand your real risk and act on it, the Women's Cardiometabolic Longevity Workup at Solcara is built for exactly that, at the moment in life when it matters most.